Exploring New Frontiers in Obesity Treatment: Eli Lilly and Regeneron's Tirzepatide and Mibavademab Study

Eli Lilly and Regeneron are conducting a Phase 2 clinical study to assess the effectiveness of tirzepatide and mibavademab in treating obesity. The study aims to evaluate whether the combination of the two drugs results in greater weight loss compared to tirzepatide alone. The study began on April 24, 2024, with an estimated primary completion date yet to be announced. Positive results could boost investor confidence and stock performance for the two companies.